#Denmark #Copenhagen #Kelun-Biotech #Lung Cancer #sacituzumab tirumotecan

Kelun-Biotech to Present Sacituzumab Tirumotecan Analysis at ELCC 2026

Introduction
Kelun-Biotech, a prominent name in the biopharmaceutical sector, is set to present significant findings on sacituzumab tirumotecan (sac-TMT) at the highly anticipated 2026 European Lung Cancer Congress (ELCC), taking place in Copenhagen from March 25 to 28, 2026. The congress will host groundbreaking discussions on lung cancer treatments, and sac-TMT’s final overall survival (OS) analysis from the pivotal OptiTROP-Lung03 study will be featured as a Late-Breaking Abstract. Professor Yunpeng Yang from the Sun Yat-sen University Cancer Center will present these important findings to an eager global audience.

Study Overview
The OptiTROP-Lung03 study was meticulously designed to assess the efficacy and safety profile of sac-TMT compared to docetaxel. This study specifically targeted patients dealing with advanced EGFR-mutant non-small cell lung cancer (NSCLC) who had already undergone prior treatments with EGFR-TKI and platinum-based chemotherapy. Notable results from the ASCO 2025 meeting revealed that sac-TMT significantly improved progression-free survival (PFS) and overall survival (OS) in comparison to docetaxel. These achievements were evidenced by a hazard ratio (HR) for PFS of 0.30 and an HR for OS of 0.49, marking sac-TMT as a leading candidate for advancing lung cancer therapies.

Key Highlights from the Study
At the upcoming congress, key data points will be discussed, breaking down the analysis of median OS and PFS. Here are critical details set to be presented:

• - In the docetaxel group, 41.3% of patients transitioned to receive sac-TMT after their condition worsened.
• - After adjusting for this crossover, the median OS was 20.0 months for the sac-TMT group compared to 11.2 months for the docetaxel group, with a notable 18-month OS rate of 54.7% vs. 9.1%.
• - Without accounting for the crossover, the median OS was still significantly higher for sac-TMT (20.0 months) compared to docetaxel (13.5 months).
• - Investigators noted the median PFS was 7.9 months for sac-TMT versus just 2.8 months for docetaxel.

These results underscore not just a trend but a substantial leap in treatment effectiveness and patient outcomes, reaffirming sac-TMT's significant role in managing advanced lung cancer.

Regulatory Advances and Future Directions
Given the positive findings, sac-TMT’s approval from the National Medical Products Administration (NMPA) highlights its importance in the therapeutic landscape. It has also been included in China's National Reimbursement Drug List (NRDL), further facilitating patient access to this innovative treatment. The ongoing research continues to expand, with another study, OptiTROP-Lung04, emphasizing sac-TMT’s effectiveness, revealing a median OS of 20 months within similar patient demographics.

Conclusion
Sac-TMT represents the forefront of therapy options available for advanced or metastatic EGFR-mutant NSCLC patients. With the forthcoming presentation at ELCC, Kelun-Biotech is driving the narrative forward, bringing attention not only to the innovative treatment but also to the ongoing commitment towards improving patient health outcomes in oncology. This development signals a promising future for targeted therapies in lung cancer and represents the progress of medical science in addressing complex health challenges.

About Kelun-Biotech
Kelun-Biotech, part of Kelun Pharmaceutical, is dedicated to research and development, manufacturing, and commercializing innovative biopharmaceuticals. With a portfolio of over 30 innovative drug projects, Kelun-Biotech exemplifies a commitment to addressing unmet medical needs across various serious disease areas, including oncology, thus positioning itself as a key player in the global pharmaceutical industry.

For more information, visit Kelun-Biotech.